Product Description
Mechanisms of Action: CETP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hyperlipoproteinemias|Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemia Type II|Hyperlipoproteinemia Type IV|Hypertriglyceridemia|Dyslipidemia|Coronary Artery Disease|Hyperlipoproteinemia Type III|Coronary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ILLUMINATE | P3 |
Terminated |
Coronary Artery Disease |
2007-06-01 |
|
2004-000156-16 | P3 |
Terminated |
Coronary Disease |
2006-12-02 |
|
A5091031 | P3 |
Terminated |
Hypercholesterolemia|Dyslipidemia|Hyperlipoproteinemias|Hyperlipidemia |
2006-12-01 |
|
A5091024 | P3 |
Terminated |
Hyperlipoproteinemia Type III|Hyperlipidemia|Hyperlipoproteinemias |
2006-12-01 |